[go: up one dir, main page]

ES2143620T3 - Polipeptidos modificados con actividad biologica incrementada. - Google Patents

Polipeptidos modificados con actividad biologica incrementada.

Info

Publication number
ES2143620T3
ES2143620T3 ES95912917T ES95912917T ES2143620T3 ES 2143620 T3 ES2143620 T3 ES 2143620T3 ES 95912917 T ES95912917 T ES 95912917T ES 95912917 T ES95912917 T ES 95912917T ES 2143620 T3 ES2143620 T3 ES 2143620T3
Authority
ES
Spain
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912917T
Other languages
English (en)
Inventor
Arthur J Sytokowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of ES2143620T3 publication Critical patent/ES2143620T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBEN POLIPEPTIDOS MODIFICADOS CON ACTIVIDAD BIOLOGICA AUMENTADA MOSTRADA BIEN COMO POTENCIA AUMENTADA O COMO VIDA MEDIA DE CIRCULACION PROLONGADA CON METODOS DE PREPARACION DE LOS POLIPEPTIDOS MODIFICADOS Y METODOS DE USO.
ES95912917T 1994-03-22 1995-03-15 Polipeptidos modificados con actividad biologica incrementada. Expired - Lifetime ES2143620T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity

Publications (1)

Publication Number Publication Date
ES2143620T3 true ES2143620T3 (es) 2000-05-16

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912917T Expired - Lifetime ES2143620T3 (es) 1994-03-22 1995-03-15 Polipeptidos modificados con actividad biologica incrementada.

Country Status (9)

Country Link
US (1) US5580853A (es)
EP (1) EP0751959B1 (es)
AT (1) ATE188486T1 (es)
DE (1) DE69514342T2 (es)
DK (1) DK0751959T3 (es)
ES (1) ES2143620T3 (es)
GR (1) GR3033146T3 (es)
PT (1) PT751959E (es)
WO (1) WO1995025746A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
AU733212B2 (en) 1996-03-28 2001-05-10 Board Of Trustees Of The University Of Illinois, The Material and methods for making improved liposome compositions
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ATE252601T1 (de) * 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60026300T2 (de) * 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
EP1326969B1 (en) 2000-09-25 2009-04-15 Genetronics, Inc. Improved system for regulation of transgene expression
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
ES2307718T3 (es) * 2001-02-16 2008-12-01 Conjuchem Biotechnologies Inc. Peptido 2 similar al flucagon (glp-2) de duracion prolongada para el tratamiento de enfermedades y trastornos gastrointestinales.
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE602004025799D1 (de) 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
NZ543934A (en) * 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
US20050107297A1 (en) * 2003-05-12 2005-05-19 Holmes Christopher P. Novel poly(ethylene glycol) modified compounds and uses thereof
AU2004238870B8 (en) 2003-05-12 2010-04-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
SI1625156T1 (sl) * 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
EA011168B1 (ru) 2004-04-23 2009-02-27 Конджачем Биотекнолоджис Инк. Способ очистки конъюгатов альбумина
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
KR20070108140A (ko) * 2004-11-11 2007-11-08 아피맥스, 인크. 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드
US20090249503A1 (en) * 2004-12-06 2009-10-01 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2468304A3 (en) * 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
NZ716641A (en) * 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
CN103717614A (zh) 2011-08-09 2014-04-09 普罗法尔马封闭式股份公司 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
EP0751959B1 (en) 2000-01-05
EP0751959A1 (en) 1997-01-08
DK0751959T3 (da) 2000-06-26
GR3033146T3 (en) 2000-08-31
PT751959E (pt) 2000-06-30
WO1995025746A1 (en) 1995-09-28
ATE188486T1 (de) 2000-01-15
DE69514342D1 (de) 2000-02-10
DE69514342T2 (de) 2000-11-30
US5580853A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
ES2143620T3 (es) Polipeptidos modificados con actividad biologica incrementada.
DE3578773D1 (de) Geformte koerperstuetzende matratze.
DE68924026D1 (de) Biosensor und dessen herstellung.
DE3887990D1 (de) Dehydrogenierungskatalysator und dessen verwendung.
NO952039D0 (no) Proteiner med glykosyltransferase-aktivitet
DE3780209D1 (de) Dreh- und kipptisch.
DK96787A (da) Human vaevs-plasminogenaktivator
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
DE3682882D1 (de) Menschliches immunoglobulin-g-fc-region-protein und dessen herstellung.
DE69010317D1 (de) Acrylgel und seine Herstellung.
DK50987D0 (da) Polypeptid med plasminogenaktivatorvirkning
DE3674789D1 (de) Balken und dessen herstellung.
DE3881099D1 (de) Acrylkautschuk, zusammensetzung aus acrylkautschuk und gegenstaende aus vernetztem acrylkautschuk.
FI873879L (fi) Lymfocyter aktiverande polypeptider.
DK538589D0 (da) Baktericidt middel
DE69012958D1 (de) Fibrinolytisches Protein und Herstellungsweise dafür.
NO910787D0 (no) Tredimensjonalt celle- og vevskultursystem.
NO900606D0 (no) Enzymatisk oppvask- og skyllemiddel.
KR880014653U (ko) 회전 의자
KR870014343U (ko) 휴대용 의자
ATE57223T1 (de) Balken und dessen herstellung.
IT210126Z2 (it) Sedia con spalliera inclinabile
IT8619477A0 (it) Sostanza ad attivita'nootropa e psicostimolante.
AU608232C (en) Modified tissue plasminogen activator
ES540569A0 (es) Perfeccionamientos introducidos en la construccion de inver-naderos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751959

Country of ref document: ES